Peptide Therapeutics Market

Peptide Therapeutics Market: Industry Trends and Global Forecasts, till 2030 - Distribution by Type of Peptide, Route of Administration, Key Geographical Regions and Key Therapeutic Area

  • Lowest Price Guaranteed From USD 5,499

  • Pages
    250

  • View Count
    16081

Peptide Therapeutics Market Overview

The peptide therapeutics market is estimated to be worth $15.5 billion in 2021 and is expected to grow at CAGR of 12% during the forecast period.

Over the years, the rising popularity of biologics, such as peptide therapeutics, have led to an evident shift in the focus of the healthcare industry, from traditional small molecule-based interventions to upcoming, albeit complex, family of pharmacological interventions. The success of peptide therapeutics, so far, can be attributed to their clinical benefits, which include high target specificity, low toxicity and favorable safety profiles. Since 2017, over 10 peptide-based drugs have received marketing approvals across different regions of the world.  Examples of recently approved peptide drugs include (in the reverse chronological order of approval) Lupkynis™ (2021), Mycappsa® (2020), Scenesse® (2019), Rybelsus® (2019) and Vyleesi® (2019).

Further, more than 150 therapeutic peptides are currently under clinical investigation, while several novel leads are being evaluated in the early stages of research. In this context, it is also worth mentioning that peptide therapy products account for 5% of the global pharmaceutical revenues generated annually.  

Presently, several drug developers, along with technology providers, are actively engaged in the development of novel peptide therapeutics, such as peptide drug conjugates and cell penetrating peptides. Innovation in this field of research is mostly focused on improving drug delivery methods, API stability, target affinity, and optimizing toxicity profiles. Several big pharma players have also demonstrated interest in peptide therapeutics and are investing both time and capital in this domain. Since 2019, more than USD 3 billion has been invested into companies that are involved in the development of various types of peptide drugs. In addition, the market is witnessing significant partnership activity; several licensing agreements, focused on drug development and commercialization, were recently inked between stakeholders in this industry. All these factors will drive the growth of the peptide therapeutics market, also referred to as peptide drugs market, over the forecast period.

Context of Peptide Therapeutics Market List of Peptide Therapeutics in Peptide Therapeutics Market Pipeline Landscape of Peptide Therapeutics Market

Recent Developments in Peptide Therapeutics Market

Several recent developments have taken place in the field of peptide drugs market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In February 2024, Orbis Medicines was launched with a EUR 26 million financing led by Novo Holdings and Forbion. The funding will support Orbis’ expansion and advancement of its next-generation macrocycle drugs portfolio named as nCycles.
  • In December 2023, Ironwood Pharmaceuticals filed a patent for peptides and compositions for the treatment of various gastrointestinal disorders, such as irritable bowel syndrome, Crohn’s disease and constipation.
  • In December 2023, Ocelot Bio received orphan drug designation for its lead candidate OCE-205, a peptide therapeutic under development for the treatment of ascites.
  • In September 2023, Orano Med entered into a collaboration with Orbit Discovery in order to implement its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumors. 
  • In June 2023, IRBM announced the extension of its collaboration with Merck focusing on peptide therapeutics with an aim to increase delivery of orally available peptide candidates. 
  • In January 2023, Nimble Therapeutics expanded its licensing agreement with Genentech for the discovery of peptide therapies utilized for the treatment of multiple therapeutic areas.

Key Companies in Peptide Therapeutics Market 

Examples of key companies engaged in peptide drugs market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Apellis Pharmaceuticals, BioLineRx, Eli Lilly, FirstString Research, Novo Nordisk, Palatin Technologies, RegeneRx Biopharmaceuticals, Stealth BioTherapeutics, Takeda and Zealand Pharma. This market report includes an easily searchable excel database of all the companies developing peptide therapeutics, worldwide.

Scope of the Peptide Therapeutics Market Report

The “Peptide Therapeutics Market by  Type of Peptide (Small, Medium and Large), Route of Administration (Intravenous, Oral, Subcutaneous, Topical and Others), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World) and Key Therapeutic Area (Metabolic Diseases, Oncological Diseases, Endocrine Diseases, Digestive and Gastrointestinal Diseases and Others): Industry Trends and Global Forecasts, 2021 – 2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market growth, market outlook and future opportunities of the peptide drugs market. The market research report also includes an elaborate discussion on the future potential of this evolving market.

Clinical Commercial Attractiveness Analysis in Peptide Therapeutics Market Clinical Research Landscape in Peptide Therapeutics Market Partnerships and Collaborations in Peptide Therapeutics Market

Amongst other elements, the market research report features:

  • A detailed review of the overall market landscape of peptide-based therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery), type of peptide (small, medium and large), route of administration (intravenous, oral, subcutaneous, topical and others) and key therapeutic area.
  • A detailed review of the players engaged in the development of peptide drugs, along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of prominent players engaged in the development of peptide therapeutics. Each profile features a brief overview of the company, details related to its financials (if available), product portfolios, recent developments and an informed future outlook.
  • An analysis of the big pharma players engaged in peptide therapeutics market, featuring a heat map representation, based on relevant parameters, such as number of therapeutic peptides under development, information on funding, partnership and clinical trials activity.
  • An analysis of the recent collaborations (signed since 2015) focused on peptide therapeutics, based on relevant parameters, such as the year in which the agreement was signed, type of agreement, type of peptide, route of administration, phase of development and therapeutic area. 
  • An analysis of various investments, such as seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other equity offerings, that were undertaken by companies engaged in peptide therapeutics market, between 2015-2021.
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various peptide therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication and key geographical regions.
  • An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III), based on several relevant parameters, such as size of enrolled patient population (for the trial in the highest phase of development), route of administration, type of peptide therapy, dosing frequency (for quantifying clinical attractiveness), target patient population, expected launch date and size of developer company (for quantifying commercial attractiveness).
  • A case study on the role of service providers that operate within the peptide therapeutics market, along with information on the various CROs, CMOs and custom peptide synthesis service providers that are actively engaged in this segment. 
  • A case study presenting the key characteristics of novel peptide therapeutics, along with information on their applications and advantages, as well as key challenges associated with their development process.

The key objective of peptide drugs market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for peptide therapeutics market during the forecast period. Based on the sales for approved peptide drugs, during the forecast period 2015-2020, we have developed informed estimates on the evolution of the market over the coming decade.

Additionally, the market report features the likely distribution of the current and forecasted opportunity across [A] type of peptide (small, medium and large), [B] route of administration (intravenous, oral, subcutaneous, topical and others), [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) and [D] key therapeutic area (metabolic diseases, oncological diseases, endocrine diseases, digestive and gastrointestinal diseases and others). In addition, the report provides value creation analysis of approved and clinical peptide-based therapies across different therapeutic areas.

Funding and Investment Analysis in Peptide Therapeutics Market Big Pharma Initiatives Analysis in Peptide Therapeutics Market Market Forecast and Opportunity Analysis in Peptide Therapeutics Market

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are peptide therapeutics?

Answer: Peptide therapeutics are polypeptide molecules which are employed for treating diseases. peptide therapeutics mimic the functions of Naturally occurring polypeptides, such as hormones, growth factors and ligands.

Question 2: How big is the peptide therapeutics market?

Answer: The peptide therapeutics market size is estimated to be worth $15.5 billion in 2021.

Question 3: What is the projected market growth of the peptide therapeutics market?

Answer: The peptide therapeutics market is expected to grow at compounded annual growth rate (CAGR) of 12% during the forecast period.

Question 4: Who are the leading drug developers in the peptide therapeutics market?

Answer: Examples of key companies engaged in peptide therapeutics market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Apellis Pharmaceuticals, BioLineRx, Eli Lilly, FirstString Research, Novo Nordisk, Palatin Technologies, RegeneRx Biopharmaceuticals, Stealth BioTherapeutics, Takeda and Zealand Pharma.

Question 5: How many companies are currently engaged in the peptide therapeutics market?

Answer: Over 130 companies are currently engaged in the peptide therapeutics market, involved in the research and development of novel peptide therapeutics.

Question 6: How many partnership deals have been inked between the companies engaged in peptide therapeutics market?

Answer: More than 70 partnership deals have been inked between the players engaged in peptide therapeutics market, highlighting the consolidation efforts of the stakeholders in this field.

Question 7: How much money has been invested in peptide therapeutics market?

Answer: Over USD 7 billion has been invested in peptide therapeutics market, to augment the ongoing research in the industry.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com